Efficacy usually drops off a cliff after first line (first therapy) treatment in many cancers. The best chance of being cured is typically the first therapy.
This is a population who has already been treated with a PD-1 (or PDL-1) therapy and platinum chemotherapy, which is pretty much the best treatment available, and their cancer has come back.
ESMO (European) guidelines suggest "Taxane or methotrexate or cetuximab or BSC (best supportive care)" for these patients.
Median OS for this drug was 11.5 months while the KEYNOTE-048 trial had the current standard of care at 10.7 months. So this drug is at least as good as current therapy which is very promising in such a small trial and difficult to treat population.
This is a population who has already been treated with a PD-1 (or PDL-1) therapy and platinum chemotherapy, which is pretty much the best treatment available, and their cancer has come back.
ESMO (European) guidelines suggest "Taxane or methotrexate or cetuximab or BSC (best supportive care)" for these patients.
Median OS for this drug was 11.5 months while the KEYNOTE-048 trial had the current standard of care at 10.7 months. So this drug is at least as good as current therapy which is very promising in such a small trial and difficult to treat population.